Jan. 24, 2007 (China Knowledge) – China Health Holding Inc. <CHHH>, a pharmaceutical company which deals in traditional Chinese medicine as well as Western medicine, announced that a memorandum of understanding (MoU) has been signed with the Beijing Jifatang Chinese Medicine Research & Development Institution.

This 10-year agreement will allow China Health Holding to take full advantage of the institution's R&D to treat conditions ranging from diabetes and cancer to neurological and cardiovascular disorders.

In return for exclusive rights for intellectual property developed by Beijing Jifatang, China Health Holdings will issue 200,000 common shares to Beijing Jifatang.

The signing of this MoU is the latest in a series of agreements and acquisitions aimed at establishing China Health Holding as a leader in the fast-growing Chinese medical and pharmaceutical industry. Last week, China Health acquired Xi'An Meichen Pharmaceutical Co. Ltd. This Shaanxi-based pharmaceutical manufacturer of 43 China-SFDA certified herbal-based drugs and chemical-based drugs supplies to China-SFDA licensed hospitals and drugstores throughout Shaanxi and the Mainland.